Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

Assessments by the nonprofit Institute for Clinical and Economic Review (ICER) have become increasingly influential in U.S. drug pricing and are taken into consideration by health insurers and pharmacy benefit managers making decisions about payments and patient access to treatments. Boston-based ICER has been looking at Biogen's Spinraza and Novartis' Zolgensma since last year. The extremely high cost of new treatments for rare conditions has placed SMA at the center of the drug affordability debate.